These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8583382)

  • 1. The transmucosal absorption of recombinant human interferon-alpha B/D hybrid in the rat and rabbit.
    Bayley D; Temple C; Clay V; Steward A; Lowther N
    J Pharm Pharmacol; 1995 Sep; 47(9):721-4. PubMed ID: 8583382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lymphatic route. VI. Distribution of recombinant interferon-alpha 2 in rabbit and pig plasma and lymph.
    Bocci V; Pessina GP; Paulesu L; Nicoletti C
    J Biol Response Mod; 1988 Aug; 7(4):390-400. PubMed ID: 3171601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes.
    Nicklin PL; Bayley D; Giddings J; Craig SJ; Cummins LL; Hastewell JG; Phillips JA
    Pharm Res; 1998 Apr; 15(4):583-91. PubMed ID: 9587955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lymphatic route. V. Distribution of human natural interferon-beta in rabbit plasma and lymph.
    Bocci V; Pessina GP; Paulesu L; Muscettola M; Valeri A
    J Interferon Res; 1988 Oct; 8(5):633-40. PubMed ID: 3235848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lymphatic route. IX. Distribution of recombinant interferon-alpha 2 administered subcutaneously with oedematogenic drugs.
    Pessina GP; Bocci V; Carraro F; Naldini A; Paulesu L
    Physiol Res; 1993; 42(4):243-50. PubMed ID: 8280722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog.
    Gibson DM; Cotler S; Spiegel HE; Colburn WA
    J Interferon Res; 1985; 5(3):403-8. PubMed ID: 4056487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of recombinant murine interferon-gamma and human interferon-alpha A/D(Bgl) administered in concert and their influence on natural killer cell function in mice.
    Chen SA; Shalaby MR; Crase DR; Palladino MA; Baughman RA
    J Interferon Res; 1988 Oct; 8(5):597-608. PubMed ID: 3148670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of recombinant hirudin via four non-parenteral routes.
    Liu Y; Lu WL; Zhang X; Wang XQ; Zhang H; Zhang Q
    Peptides; 2005 Mar; 26(3):423-30. PubMed ID: 15652649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels following intranasal and intravenous administration of human interferon-beta to rabbits.
    Maitani Y; Igawa T; Machida Y; Nagai T
    Drug Des Deliv; 1989 Mar; 4(2):109-19. PubMed ID: 2765103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of human recombinant interferon-beta in monkeys and rabbits.
    Gomi K; Morimoto M; Inoue A; Kobayashi H; Deguchi T; Hara T; Nakamizo N
    Gan; 1984 Mar; 75(3):292-300. PubMed ID: 6724230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pharmacokinetics of recombinant alpha 2-interferon (reaferon)].
    Kulakov VN; Pimenova GN; Matveev VA; Kobrinskiĭ GD; Kuznetsov VP
    Vopr Virusol; 1989; 34(2):183-6. PubMed ID: 2763512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic delivery of peptides and proteins across absorptive mucosae.
    Sayani AP; Chien YW
    Crit Rev Ther Drug Carrier Syst; 1996; 13(1-2):85-184. PubMed ID: 8853960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerance of ocular administration of recombinant alpha interferon.
    Turner RB; Durcan FJ; Albrecht JK; Crandall AS
    Antimicrob Agents Chemother; 1989 Mar; 33(3):396-7. PubMed ID: 2729934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
    Iwase Y; Kamei N; Khafagy el-S; Miyamoto M; Takeda-Morishita M
    Int J Pharm; 2016 Aug; 510(1):304-10. PubMed ID: 27343364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal administration of beta-interferon in rabbits.
    Maitani Y; Igawa T; Machida Y; Nagai T
    Drug Des Deliv; 1986 Aug; 1(1):65-70. PubMed ID: 3509321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic absorption and activity of recombinant consensus interferons after intratracheal instillation and aerosol administration.
    Niven RW; Whitcomb KL; Woodward M; Liu J; Jornacion C
    Pharm Res; 1995 Dec; 12(12):1889-95. PubMed ID: 8786962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma.
    Bocci V; Muscettola M; Grasso G; Magyar Z; Naldini A; Szabo G
    Experientia; 1986 Apr; 42(4):432-3. PubMed ID: 3956696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Promoting mechanism of enhancers and transport pathway of large hydrophilic molecular across nasal epithelium studied by ESR and CLSM technologies].
    Zhang YJ; Zhang Q; Yang J; Sun MJ; Wang XL; Chen MX; Wang Q; Jiang H
    Yao Xue Xue Bao; 2007 Nov; 42(11):1195-200. PubMed ID: 18300478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somnogenic effects of rabbit and recombinant human interferons in rabbits.
    Kimura M; Majde JA; Toth LA; Opp MR; Krueger JM
    Am J Physiol; 1994 Jul; 267(1 Pt 2):R53-61. PubMed ID: 7519411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats.
    Ben Reguiga M; Bonhomme-Faivre L; Farinotti R
    J Pharm Pharmacol; 2007 Mar; 59(3):401-8. PubMed ID: 17331344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.